CA2265550A1 - Methods and compositions for generating angiostatin - Google Patents

Methods and compositions for generating angiostatin Download PDF

Info

Publication number
CA2265550A1
CA2265550A1 CA002265550A CA2265550A CA2265550A1 CA 2265550 A1 CA2265550 A1 CA 2265550A1 CA 002265550 A CA002265550 A CA 002265550A CA 2265550 A CA2265550 A CA 2265550A CA 2265550 A1 CA2265550 A1 CA 2265550A1
Authority
CA
Canada
Prior art keywords
angiostatin
plasminogen
pro
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002265550A
Other languages
English (en)
French (fr)
Inventor
Gerald Soff
Stephen T. Gately
Przemyslaw Twardowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2265550A1 publication Critical patent/CA2265550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166Streptokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6435Plasmin (3.4.21.7), i.e. fibrinolysin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002265550A 1996-09-17 1997-09-17 Methods and compositions for generating angiostatin Abandoned CA2265550A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/710,305 1996-09-17
US08/710,305 US5801012A (en) 1996-09-17 1996-09-17 Methods and compositions for generating angiostatin
PCT/US1997/016539 WO1998015574A1 (en) 1996-09-17 1997-09-17 Methods and compositions for generating angiostatin

Publications (1)

Publication Number Publication Date
CA2265550A1 true CA2265550A1 (en) 1998-04-16

Family

ID=24853480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265550A Abandoned CA2265550A1 (en) 1996-09-17 1997-09-17 Methods and compositions for generating angiostatin

Country Status (9)

Country Link
US (2) US5801012A (enExample)
EP (2) EP0964869B1 (enExample)
JP (1) JP4160121B2 (enExample)
AT (1) ATE329926T1 (enExample)
AU (1) AU4422797A (enExample)
CA (1) CA2265550A1 (enExample)
DE (1) DE69736129T2 (enExample)
ES (1) ES2267151T3 (enExample)
WO (1) WO1998015574A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
CA2295925A1 (en) * 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
JP2002531385A (ja) * 1998-11-25 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー アンジオスタチンおよびプラスミノゲンのクリングル5領域を含む組成物およびその使用方法
EP1214346A1 (en) 1999-09-15 2002-06-19 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
WO2001058921A2 (en) * 2000-02-08 2001-08-16 Northwestern University Methods and compositions for generating angiostatin
CA2421251A1 (en) 2000-09-05 2002-03-14 Karolinska Innovations Ab Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
US7420036B2 (en) 2000-11-28 2008-09-02 Waisman David M Anti-angiogenic polypeptides
ITMI20011995A1 (it) * 2001-09-26 2003-03-26 Ist Naz Ricerca Sul Cancro Sostanze ad attivita' antinfiammatoria
US7285277B2 (en) * 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2004054517A2 (en) * 2002-12-13 2004-07-01 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
US7141035B2 (en) * 2003-03-28 2006-11-28 Sherwood Services Ag Catheter with occlusion resistant tip
US7090654B2 (en) * 2003-03-28 2006-08-15 Sherwood Services Ag Catheter with occlusion resistant tip
US7776005B2 (en) * 2003-03-28 2010-08-17 Covidien Ag Triple lumen catheter with occlusion resistant tip
CN1889929B (zh) * 2003-11-14 2013-04-10 阿尔萨公司 药物递送媒介物中的赋形剂
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US9913962B2 (en) 2004-11-04 2018-03-13 Covidien Ag Catheter insertion apparatus
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2009100617A1 (zh) * 2008-02-04 2009-08-20 Shanghai First People's Hospital 抑制血管新生的多肽及其应用
WO2010151573A1 (en) 2009-06-26 2010-12-29 Tyco Healthcare Group Lp Catheterization system
CA2715857A1 (en) 2009-09-30 2011-03-30 Tyco Healthcare Group Lp Medical catheter having a design providing low recirculation and reversibility
US9072867B2 (en) 2011-09-30 2015-07-07 Covidien Lp Catheter with external flow channel
US8747343B2 (en) 2011-09-30 2014-06-10 Covidien Lp Hemodialysis catheter with improved side opening design
US9216163B2 (en) 2013-05-20 2015-12-22 Kyorin Pharmaceutical Co., Ltd. Method of inhibiting angiogenesis
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431342C3 (de) * 1973-07-27 1978-10-26 Behringwerke Ag, 3550 Marburg Verfahren zur Messung des Plasminogengehaltes durch Bestimmung der Bildung von Fibrin in einer Probe
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
DE68927904T2 (de) 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
ATE368051T1 (de) 1995-04-26 2007-08-15 Childrens Medical Center Angiostatinfragmente und verfahren für deren verwendung
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
WO1996041194A1 (en) 1995-06-07 1996-12-19 The Children's Medical Center Corporation Diagnosis, prognosis and monitoring of angiogenesis dependent diseases
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US5854221A (en) 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
CN1554444A (zh) 1995-12-13 2004-12-15 ��ͯҽѧ���Ĺ�˾ 内皮细胞增殖抑制剂及其应用方法
BR9708911A (pt) 1996-05-03 1999-08-03 Abbott Lab Composto fragmento de peptídeo processo par tratar uma doença em um paciente em necessidade de terapia antioangiogênese composição polinucleotídeo único ou de duplo-filamento isolado vetor e processo para produzir um fragmento de peptídeo de kringle 5 ou proteína de fusão de kringle 5 solúvel
CA2295925A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo

Also Published As

Publication number Publication date
WO1998015574A1 (en) 1998-04-16
EP1705184A1 (en) 2006-09-27
ES2267151T3 (es) 2007-03-01
JP4160121B2 (ja) 2008-10-01
US5801012A (en) 1998-09-01
AU4422797A (en) 1998-05-05
EP0964869B1 (en) 2006-06-14
DE69736129D1 (de) 2006-07-27
EP0964869A1 (en) 1999-12-22
US6576609B1 (en) 2003-06-10
EP0964869A4 (en) 2003-06-04
ATE329926T1 (de) 2006-07-15
JP2001502534A (ja) 2001-02-27
DE69736129T2 (de) 2007-01-04

Similar Documents

Publication Publication Date Title
CA2265550A1 (en) Methods and compositions for generating angiostatin
Levin et al. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators.
CA2291892C (en) Angiostatin fragments and method of use
Christensson et al. Complex formation between protein C inhibitor and prostate‐specific antigen in vitro and in human semen
CA2074839C (en) Modified factor vii anticoagulant proteins
JP4509846B2 (ja) 第VII因子または第VIIa因子様分子
US5981484A (en) Antiangiogenic peptides and methods for inhibiting angiogenesis
Bjørn et al. Messenger RNA for membrane-type 2 matrix metalloproteinase, MT2-MMP, is expressed in human placenta of first trimester
Goldfarb et al. Purification of plasminogen activator from Rous sarcoma virus transformed chick embryo fibroblasts treated with the tumor promoter phorbol 12-myristate 13-acetate
Sumi et al. Urokinase-like plasminogen activator increased in plasma after alcohol drinking
Li et al. Activation of gelatinase A (72-kDa type IV collagenase) induced by monensin in normal human fibroblasts
WO2001058921A9 (en) Methods and compositions for generating angiostatin
US20060099671A1 (en) Methods and compositions for generating angiostatin
Maehara et al. Immunochemical studies of human urinary trypsin inhibitor
JP3045307B2 (ja) 活性化プロテインcを生成するための細胞培養法
DE60034434T2 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
JP3153236B2 (ja) 端が切り取られた軽鎖を有する組換えプロテインc
JPH0655152B2 (ja) ミナクチビンの製造方法
Haas et al. Angiotensin-producing serum enzyme II. Formation by inhibitor removal and proenzyme activation.
DeCarlo Jr Matrix metalloproteinase activation and induction in keratinocytes by a purified thiol-proteinase from Porphyromonas gingivalis
WO2003084466A2 (en) FACTORVIIa COMPOSITIONS
CHRISTENSSON et al. in zyxwvutsrqponmlkji
Lourbakos Activation of human protease-activated receptors by proteases from a periodontal pathogen

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued